Presence of ER-negative CTCs in patients with ER-positive breast cancer might be explained either by heterogeneity of primary tumor, leading to release of both ER-positive and ER-negative cells in circulation or by the switch of ER expression by genomic and/or epigenomic changes (Figure 3). This evidence concerns the gene ESR1 and neoplasm.